FrancophonIA/ELRC3.0 huggingface dataset:
English: Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
Maltese: Sakemm kontinwazzjoni tat-terapija b'inibituri ta' ACE ma tkunx ikkunsidrata essenzjali, pazjenti li qed jippjanaw li joħorġu tqal għandhom jingħataw kura alternattiva li tbaxxi l-pressjoni li għandha profil ta' sigurtà stabbilit għall-użu waqt ittqala.
English: Vascace induces a reduction of both supine and standing systolic and diastolic blood pressure, usually with no orthostatic component.
Maltese: Vascace jikkawża tnaqqis tal-pressjoni sistolika u dijastolika ta' meta wieħed ikun mimdud kif ukoll meta bilwieqfa, normalment bl-ebda komponent ortostatiku.
English: Concomitant use of thiazide diuretics may increase the risk of lithium toxicity and enhance the already increased risk of lithium toxicity with ACE inhibitors.
Maltese: L-użu flimkien ta' dijuretiċi thiazide jista' jżid ir-riskju ta' tossiċità ta' lithium u jsaħħaħ ir-riskju diġà miżjud ta' tossiċità ta' lithium b'inibituri ta' ACE.
English: The special dosage recommendation should thus be followed in chronic heart failure patients with impaired renal function.”
Maltese: Għaldaqstant għandha tiġi segwita rrakkomandazzjoni speċjali tad-dożaġġ fil-pazjenti b'insuffiċjenza kronika tal-qalb b'indeboliment talfunzjoni renali.”
English: The events of cerebral ischaemia, transient ischaemic attack and ischaemic stroke reported rarely in association with ACE inhibitors may be related to hypotension in patients with underlying cerebrovascular disease.
Maltese: L-avvenimenti ta' iskemija ċerebrali, attakk iskemiku temporanju u puplesija iskemika irrappurtati b'mod rari f'assoċjazzjoni ma' inibituri ta' ACE jistgħu jkunu relatati ma' pressjoni baxxa f'pazjenti b'mard ċerebrovaskulari.
English: The CHMP agreed with the following wording proposed by the MAH for the elderly and paediatric populations:
Maltese: Wara li tqieset ir-rakkomandazzjoni tas-CHMP PhVWP, kien hemm qbil dwar dan il-kliem propost mill-MAH:
English: Excessive lowering of blood pressure may increase the chance of heart attack or stroke in certain patients - Increased heart rate - Feeling weak - Pains in the chest - Breathing problems, including shortness of breath and tightness in the chest - A runny or blocked nose and sneezing (rhinitis) - Dry or swollen mouth - Lack of appetite - Change in the way things taste - Diarrhoea and vomiting - Skin rash (which may be severe) - Muscle cramps or pain in your muscles or joints - Impotence
Maltese: Esponiment għall-kura b'inibituri ta' ACE matul it-tieni u t-tielet trimester huwa magħruf li jinduċi tossiċità lill-fetu uman (tnaqqis fil-funzjoni tal-kliewi, fluwidu amnjotiku mhux suffiċjenti, dewmien fl-ossifikazzjoni tal-qorriegħa tar-ras) u tossiċità lil trabi tat-twelid (insuffiċjenza tal-kliewi, pressjoni baxxa, iperkalimja).
English: Chronic heart failure
Maltese: Disturbi fis-sistema nervuża
English: Hypotension contributes further to a reduction in renal perfusion (see section 4.4 `Hypotension').
Maltese: Pressjoni baxxa tkompli tikkontribwixxi għat-tnaqqis fil-perfużjoni tal-kliewi (ara sezzjoni 4.4 ‘Pressjoni baxxa').
English: The following sections were harmonised:
Maltese: Is-sezzjonijiet li ġejjin kienu armonizzati:
English: What Vascace is and what it is used for Before you take Vascace How to take Vascace Possible side effects How to store Vascace Further information
Maltese: Doża inizjali ta'Vascace Doża massima ta' Vascace
English: Lactose intolerance
Maltese: Intolleranza għal-lattożju
English: General disorders and administration site conditions Common
Maltese: Disturbi ġenerali u kondizzjonijiet ta' mnejn jingħata Komuni
English: Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see sections 4.3 and 4.4).
Maltese: Trabi li ommijiethom ħadu inibituri ACE għandhom jiġu osservati mill-qrib għal pressjoni baxxa (ara sezzjonijiet 4.3 u 4.4).
English: It is available as tablets (2.5, 5, 7.5, 10, 15 and 20 mg) and as ‘orodispersible' tablets (5, 10, 15 and 20 mg).
Maltese: Jiġi bħala pilloli (2.5, 5, 7.5, 10, 15 u 20 mg) u bħala pilloli orodispersibbli (5, 10, 15 u 20 mg).
English: The full EPAR for Olanzapine Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Olanzapine Teva olanzapine
Maltese: Olanzapine Teva olanzapina
English: The active substance in Olanzapine Teva, olanzapine, is an antipsychotic medicine.
Maltese: Is-sustanza attiva f'Olanzapine Teva, l-olanzapina, hija mediċina antipsikotika.
English: This is a summary of the European public assessment report (EPAR) for Olanzapine Teva.
Maltese: Dan id-dokument huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Olanzapine Teva.
English: This means that Olanzapine Teva is similar to ‘reference medicines' already authorised in the European Union (EU) called Zyprexa and Zyprexa Velotab.
Maltese: Dan ifisser li Olanzapine Teva huwa simili għall-‘mediċini ta' referenza' diġà awtorizzati fl-Unjoni Europea (UE) li jisimhom Zyprexa u Zyprexa Velotab.
English: Olanzapine Teva is a ‘generic medicine'.
Maltese: Olanzapine Teva huwa ‘mediċina ġenerika'.
English: The recommended starting dose of Olanzapine Teva depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day.
Maltese: Doża ta' 10 mg kuljum tintuża għall-iskizofrenija u fil-prevenzjoni ta' episodji manijaċi, u 15 mg kuljum fit-trattament ta' episodji manijaċi, sakemm ma tintużax ma' mediċini oħra, f'liema każ id-doża talbidu tista' tkun ta' 10 mg kuljum.
English: Olanzapine Teva is also used to treat moderate to severe manic episodes (extremely high mood) in adults.
Maltese: Olanzapine Teva jintuża wkoll fit-trattament ta' episodji moderati jew severi tal-manija (burdata tajba b'mod estrem) f'adulti.
English: It is thought that olanzapine's beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytryptamine (also called serotonin) and dopamine.
Maltese: Hu maħsub li l-effett benefiku tal-olanzapina huwa dovut għall-imblokkar tar-riċetturi għannewrotrażmettituri 5-idrossitriptamina (5-hydroxytrypamine, imsejħa wkoll serotonina) u dopamina.
English: Olanzapine Teva is a medicine containing the active substance olanzapine.
Maltese: Olanzapine Teva hija mediċina li fiha s-sustanza attiva olanzapina.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Olanzapine Teva on 12 December 2007.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Olanzapine Teva valida fl-Unjoni Ewropea kollha fit-12 ta' Diċembru 2007.
English: The CHMP concluded that, in accordance with EU requirements, Olanzapine Teva has been shown to have comparable quality and to be bioequivalent to Zyprexa and Zyprexa Velotab.
Maltese: Is-CHMP ikkonkluda li, b'mod konformi mar-rekwiżiti tal-UE, Olanzapine Teva wera li għandu kwalità komparabbli ma' u huwa bijoekwivalenti għal Zyprexa u Zyprexa Velotab.
English: Schizophrenia is a mental illness that has a number of symptoms including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs).
Maltese: L-iskizofrenija hija marda mentali li għandha numru ta' sintomi, inkluż disturbi fil-ħsieb u fid-diskors, alluċinazzjonijiet (jiġifieri d-dehra u s-smigħ ta' affarijiet li jkunu immaġinarji), suspetti u delirji (thewdin żbaljat).
English: Because Olanzapine Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicines.
Maltese: Billi Olanzapine Teva huwa mediċina ġenerika, l-istudji fil-pazjenti ġew limitati għal testitjiet biex jiddeterminaw il-bijoekwivalenza tiegħu mal-mediċini ta' referenza.
English: Because Olanzapine Teva is a generic medicine and is bioequivalent to the reference medicines, its benefit and risk are taken as being the same as those of the reference medicines.
Maltese: Minħabba li Olanzapine Teva huwa mediċina ġenerika u bijoekwivalenti għall-mediċini ta' referenza, ilbenefiċċju u r-riskju tiegħu huma meqjusa li huma analogi għal dawk tal-mediċini ta' referenza.
English: This disrupts signals transmitted between brain cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other.
Maltese: Dan ifixkel sinjali trażmessi bejn iċ-ċelluli tal-moħħ minn ‘newrotrasmettituri', li huma kimiċi li jippermettu liċ-ċelluli tan-nervituri jikkomunikaw ma' xulxin.
English: What is Olanzapine Teva?
Maltese: Kif jintuża Olanzapine Teva?
English: It can also be used to prevent the recurrence of these episodes (when symptoms come back) in adults with bipolar disorder (a mental illness causing alternating periods of high mood and depression) who have responded to an initial course of treatment.
Maltese: Jista' jintuża wkoll biex jipprevjeni li sintomi ta' dawn l-episodji jerġgħu jitfaċċaw f'adulti b'disturbi polari (marda mentali li tikkawża perjodi jalternaw bejn burdata tajba ħafna u depressjoni) li jkunu rrispondew għal kors inizjali ta' trattament.
English: Why has Olanzapine Teva been approved?
Maltese: Għaliex ġie approvat Olanzapine Teva?
English: The marketing authorisation holder of SoliCol D3 shall provide evidence that the manufacturing process complies with the requirements of Commission Directive 2003/94/EC laying down the principles and guidelines of Good Manufacturing Practice (GMP) as provided for in Article 8(3) of Directive 2001/83/EC.
Maltese: Id-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq ta' SoliCol D3 għandu jipprovdi evidenza li lproċess ta' manifattura jikkonforma mar-rekwiżiti tad-Direttiva tal-Kummissjoni 2003/94/KE li tistabbilixxi l-prinċipji u l-linji gwida tal-Prattika ta' Manifattura Tajba (GMP, Good Manufacturing Practice) kif stipulat fl-Artikolu 8(3) tad-Direttiva 2001/83/KE.
English: For the suspension of SoliCol D3 to be lifted, the competent authorities shall ensure that the below conditions have been completed by the marketing authorisation holder(s):
Maltese: Sabiex titneħħa s-sospensjoni ta' SoliCol D3, l-awtoritajiet kompetenti għandhom jiżguraw li lkundizzjonijiet t'hawn taħt ġew issodisfati mid-detentur(i) tal-awtorizzazzjoni għat-tqegħid fis-suq:
English: Annex III Conditions for lifting the suspension of the marketing authorisation(s)
Maltese: Anness III Kundizzjonijiet għat-tneħħija tas-sospensjoni tal-awtorizzazzjoni(jiet)
English: Conditions for lifting the suspension of the marketing authorisation(s)
Maltese: Kundizzjonijiet għat-tneħħija tas-sospensjoni tal-awtorizzazzjoni(jiet)
English: The full EPAR for Erelzi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Over 70% of those given Erelzi (186 of 264 patients) and roughly 72% of those given Enbrel (191 of 267) had at least 75% reduction in their symptom score after 12 weeks of treatment, which was the main measure of effectiveness.
Maltese: Aktar minn 70 % ta' dawk li ngħataw Erelzi (186 minn 264 pazjent) u madwar 72 % ta' dawk li ngħataw Enbrel (191 minn 267) kellhom tal-inqas tnaqqis ta' 75 % fil-punteġġ tas-sintomi tagħhom wara 12-il ġimgħa ta' kura, li kien il-kejl ewlieni tal-effikaċja.
English: The reference medicine for Erelzi is Enbrel.
Maltese: Il-mediċina ta' referenza għal Erelzi hi Enbrel.
English: Erelzi contains the active substance etanercept and is a ‘biosimilar medicine'.
Maltese: Erelzi fih is-sustanza attiva etanercept u huwa ‘mediċina bijosimili'.
English: Why is Erelzi approved?
Maltese: Għaliex ġie approvat Erelzi?
English: The active substance in Erelzi, etanercept, is a protein that has been designed to block the activity of a substance called tumour necrosis factor alpha (TNF).
Maltese: ᾽ sustanza li tissejjaħ fattur tan-nekrożi tumorali alfa (TNF, tumour necrosis factor).
English: In adults, the usual recommended dose is 25 mg twice a week or 50 mg once a week.
Maltese: Fl-adulti, id-doża rakkomandata tas-soltu hija ta' 25 mg darbtejn fil-ġimgħa jew ta' 50 mg darba f'ġimgħa.
English: The educational materials also include a reminder that Erelzi is not for use in children and adolescents who weigh less than 62.5 kg.
Maltese: Il-materjal edukattiv jinkludi wkoll tfakkira li Erelzi mhuwiex għall-użu fit-tfal u fl-adoloxxenti li jiżnu inqas minn 62.5 kg.
English: • psoriatic arthritis (psoriasis with inflammation of the joints) in adults and adolescents;
Maltese: • artrite psorjatika (psorijażi b'infjammazzjoni tal-ġogi) fl-adulti u fl-adoloxxenti;
English: The most common side effects with etanercept (seen in more than 1 patient in 10) are injection-site reactions (including bleeding, redness, itching, pain and swelling) and infections (including colds, and lung, bladder and skin infections).
Maltese: 1 minn kull 10) huma reazzjonijiet fis-sit tal-injezzjoni (inklużi dmija, ħmura, ħakk, uġigħ u nefħa), u infezzjonijiet (inklużi rjiħat, u infezzjonijiet fil-pulmun, fil-bużżieqa tal-awrina u fil-ġilda).
English: Erelzi is not for use in children who need doses other than 25 or 50 mg (e.g. those weighing less than 62.5 kg), because it is only available in these doses; an alternative product should be used in such children.
Maltese: Erelzi mhuwiex għall-użu fit-tfal li għandhom bżonn dożi oħra minbarra dawk ta' 25 jew 50 mg (eż. dawk li jiżnu inqas minn 62.5 kg), għax dan huwa disponibbli biss f'dawn id-dożi; fi tfal bħal dawn għandu jintuża prodott alternattiv.
English: This means that Erelzi is highly similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU).
Maltese: Dan ifisser li Erelzi huwa simili għal mediċina bijoloġika (magħrufa wkoll bħala l-'mediċina ta' referenza') li diġà hija awtorizzata fl-Unjoni Ewropea (UE).
English: • rheumatoid arthritis (a disease causing inflammation of the joints) in adults, used with another medicine, methotrexate, or alone;
Maltese: • artrite rewmatojde (marda li tikkawża infjammazzjoni tal-ġogi) fl-adulti, li jintuża ma' mediċina oħra, methotrexate, jew waħdu;
English: • ankylosing spondylitis (a disease causing inflammation of the joints of the spine) in adults;
Maltese: • spondilite ankilotika (marda li tikkawża infjammazzjoni tal-ġogi tas-sinsla tad-dahar) fl-adulti;
English: Erelzi was also shown to be as effective as Enbrel in one main study involving 531 adults with plaque psoriasis.
Maltese: Fi studju ewlieni wieħed li involva 531 adult bi psorijażi bil-qoxra, intwera wkoll li Erelzi huwa effettiv daqs Enbrel.
English: • axial spondyloarthritis (a chronic inflammatory disease of the spine) in adults when there are no abnormalities seen on x-ray.
Maltese: • spondiloartrite assjali (marda infjammatorja kronika tas-sinsla tad-dahar) fl-adulti meta ma jkunx hemm anormalitajiet osservati fuq ir-raġġi X.
English: How does Erelzi work?
Maltese: Kif jintuża Erelzi?
English: What are the risks associated with Erelzi?
Maltese: X'inhuma r-riskji assoċjati ma' Erelzi?
English: The company that markets Erelzi will provide educational material for doctors expected to prescribe the product to teach patients how to use the pre-filled pen correctly and a special alert card for patients so they can recognise serious side effects and know when to seek urgent attention from their doctor.
Maltese: Il-kumpanija li tqiegħed Erelzi fis-suq se tipprovdi materjal edukattiv għat-tobba li mistennija jippreskrivu l-prodott biex jgħallmu lill-pazjenti kif jużaw il-pinna mimlija għal-lest b'mod korrett u kard ta' twissija speċjali għall-pazjenti sabiex ikunu jistgħu jagħrfu effetti sekondarji serji u jkunu jafu meta għandhom ifittxu attenzjoni urġenti mit-tabib tagħhom.
English: This is a summary of the European public assessment report (EPAR) for Erelzi.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements for biosimilar medicines, Erelzi has been shown to have a comparable quality, safety and effectiveness to Enbrel.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) tal-Aġenzija ddeċieda li, b'mod konformi mar-rekwiżiti tal-UE għal mediċini bijosimili, Erelzi wera li għandu profil ta' kwalità, sigurtà u effikaċja komparabbli għal Enbrel.
English: Laboratory studies comparing Erelzi with Enbrel have shown that the active substance in Erelzi is highly similar to that in Enbrel in terms of structure, purity and biological activity.
Maltese: Saru studji sabiex juru li Erelzi jipproduċi livelli simili tas-sustanza attiva fil-ġisem bħal Enbrel.
English: Other information about Erelzi
Maltese: Informazzjoni oħra dwar Erelzi
English: Erelzi is an anti-inflammatory medicine for treating the following diseases:
Maltese: Erelzi huwa mediċina antiinfjammatorja għall-kura tal-mard li ġej:
English: By blocking TNF, etanercept reduces the inflammation and other symptoms of the diseases.
Maltese: Billi jimblokka t-TNF, etanercept inaqqas l-infjammazzjoni u sintomi oħrajn tal-mard.
English: Therefore, the CHMP's view was that, as for Enbrel, the benefit outweighs the identified risk.
Maltese: Għaldaqstant, il-fehma tas-CHMP kienet li, bħal fil-każ ta' Enbrel, ilbenefiċċju huwa akbar mir-riskju identifikat.
English: The full EPAR for VarroMed can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The groups were treated during winter (in the absence of brood), spring and autumn (in the presence of brood) and included colonies of different sizes (5,000 to 30,000 bees) and different infestation levels.
Maltese: Il-gruppi ġew kkurati matul ix-xitwa (fin-nuqqas tad-duqqajs), matul ir-rebbiegħa u l-ħarifa (fil-preżenza tad-duqqajs) u kienu jinkludu kolonji ta' daqsijiet differenti (5,000 sa 30,000 naħla) u livelli ta' infestazzjoni differenti.
English: In each location 20 test groups were compared to 12 control groups treated with flumethrin (another medicine effective against parasites).
Maltese: F'kull post tqabblu 20 grupp ta' test ma' 12-il grupp ta' kontroll ikkurati bi flumethrin (mediċina oħra effettiva kontra l-parassiti).
English: This is a summary of the European public assessment report (EPAR) for VarroMed.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal VarroMed.
English: VarroMed contains the active substances oxalic acid dihydrate and formic acid.
Maltese: VarroMed fih is-sustanzi attivi oxalic acid dihydrate u formic acid.
English: The average effectiveness of VarroMed to kill mites (measured by the number of dead mites found at the bottom of the hive) was 88% for winter, 92% for spring and 85% for autumn treatments.
Maltese: L-effettività medja ta' VarroMed biex joqtol id-dud (imkejla min-numru ta' dud mejjet misjub fil-qiegħ tad-doqqajs) kien 88 % għall-kura fix-xitwa, 92 % għall-kura fir-rebbiegħa u 85 % għall-kura fil-ħarifa.
English: This summary was last updated in October 2016.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'Ottubru 2016.
English: VarroMed is intended to be used as part of an integrated varroa control programme, which includes other techniques.
Maltese: VarroMed huwa maħsub li jintuża bħala parti minn programm ta' kontroll ta' varroa integrat, li jinkludi tekniki oħrajn.
English: The European Commission granted a marketing authorisation valid throughout the EU for VarroMed on 2 February 2017.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha għal VarroMed fil-02/02/2017.
English: The effectiveness of VarroMed was investigated in field studies in European countries with different climates, both continental climate and Mediterranean climate.
Maltese: L-effettività ta' VarroMed ġiet investigata fi studji fuq il-post f'pajjiżi Ewropej bi klimi differenti, kemm il-klima kontinentali kif ukoll dik Mediterranja.
English: In case of accidental spillage into the eye(s) flush the eye(s) immediately with clear running water for 10 minutes.
Maltese: F'każ ta' tixrid aċċidentali fl-għajn(ejn) laħlaħ l-għajn(ejn) immdejatament b'ilma ġieri ċar għal 10 minuti.
English: Why is VarroMed approved?
Maltese: Għaliex ġie approvat VarroMed?
English: Formic acid is thought to kill Varroa mites by blocking the ability of their cells to generate energy; it may also act on mite nerve cells.
Maltese: Il-formic acid huwa maħsub li joqtol id-dud tal-Varroa billi jimblokka l-abilità taċ-ċelluli tagħhom li jiġġeneraw l-enerġija; jista' wkoll jaġixxi fuq iċ-ċelluli tan-nervituri tad-dud.
English: Other information about VarroMed?
Maltese: Informazzjoni oħra dwar VarroMed
English: What are the risks associated with VarroMed?
Maltese: X'inhuma r-riskji assoċjati ma' VarroMed?
English: Varroosis is a disease of honey bees caused by infestation with a parasite called Varroa mite (Varroa destructor).
Maltese: Il-varroażi hija marda tan-naħal tal-għasel ikkawżata minn infestazzjoni b'parassita msejjaħ Dudu tal-varroa (Varroa destructor).
English: The Varroa mite feeds on the haemolymph (blood) of adult bees and on brood (developing stages of the honey bee) resulting in damage and / or death of bees; the mite can also help spread of viruses and bacteria.
Maltese: Id-dudu tal-Varroa jiekol il-emolimfa (demm) ta' naħal adulti u duqqajs (stadji tal-iżvilupp tan-naħal tal-għasel) li jirriżulta fi ħsara u / jew mewt tan-naħal; id-dudu jista' wkoll jgħin fit-tixrid tal-virusijiet u l-batterji.
English: VarroMed is irritating to the skin and eyes.
Maltese: VarroMed huwa irritanti għall-ġilda u l-għajnejn.
English: VarroMed is available as a bee-hive dispersion (a liquid for use inside the bee hive) and can be obtained without a prescription.
Maltese: VarroMed huwa disponibbli bħala dispersjoni tad-doqqajs (likwidu għall-użu ġewwa d-doqqajs) u jista' jinkiseb mingħajr riċetta ta' tabib.
English: The activity of oxalic acid on mites is thought to be due to the acidity of the medicine.
Maltese: L-attività tal-oxalic acid fuq id-dud hija maħsuba li hija dovuta għall-aċidità tal-mediċina.
English: VarroMed is a medicine used to treat varroosis in honey bee colonies.
Maltese: VarroMed huwa mediċina li tintuża għall-kura ta' varroażi f'kolonji tan-naħal tal-għasel.
English: VarroMed must not be given during nectar flow, when honey is produced by bees, and should not be used when honey chambers are attached to the hive.
Maltese: VarroMed m'għandux jingħata waqt il-fluss tan-nektar, meta l-għasel jiġi prodott min-naħal, u m'għandux jintuża meta l-kompartimenti tal-għasel ikunu mwaħħlin mad-doqqajs.
English: The most common side effect with VarroMed (which may affect more than 1 in 10 bee colonies) is an increased number of deaths of worker bees.
Maltese: L-effett sekondarju l-aktar komuni b'VarroMed (li jista' jaffettwa aktar minn kolonja 1 minn kull 10 kolonji tan-naħal) huwa numru akbar ta' mwiet ta' naħal ħaddiem.
English: Varroa mite and honey bee mortality were monitored twice weekly for 4 weeks during treatment until one week after treatment.
Maltese: Il-mortalità tad-dudu tal-varroa u tan-naħla tal-għasel ġew immonitorjati darbtejn f'ġimgħa għal 4 ġimgħat waqt il-kura sa ġimgħa waħda wara l-kura.
English: Accidental ingestion may cause adverse reactions.
Maltese: Inġestjoni aċċidentali tista' tikkawża reazzjonijiet avversi.
English: The dose is adjusted to the colony size.
Maltese: Id-doża hija aġġustata għad-daqs tal-kolonja.
English: Treatment should be given in the late afternoon or evening when bees are less likely to be flying.
Maltese: Il-kura għandha tingħata tard wara nofsinhar jew filgħaxija meta n-naħal ikunu inqas probabbli li qed itiru.